Clinical Trials Logo

Filter by:
NCT ID: NCT04692233 Recruiting - Cancer Clinical Trials

Qigong to Improve Frailty Among Older Cancer Survivors

Start date: February 19, 2021
Phase: N/A
Study type: Interventional

The objective of the study is to examine the effects of a 16-week Baduanjin qigong intervention on frailty, physical performance, psychological well-being, and health-related quality of life (HRQoL) among post-treatment older cancer survivors. This will be a randomized controlled, assessor-blind trial conforming to the CONSORT guidelines. A total of 226 cancer survivors aged over 65 who have completed curative treatment and screened as pre-frail or frail will be recruited and randomized into intervention and control groups. It is expected that upon intervention completion, the intervention group will demonstrate greater reversed frailty status, more improvements in physical performance, better psychological well-being, and enhanced HRQoL compared to the control group. Study instruments will be Fried Phenotype Criteria, Edmonton Frail Scale, Short Physical Performance Battery, Geriatric Depression Scale, European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire, and a background questionnaire. The intervention comprises of 1-hour qigong group training twice a week for 8 weeks, then 1-hour weekly follow-up group practice for 8 weeks and self-practice. The control group participants will attend light flexibility exercise group sessions at the same duration and frequency as the intervention group. Intention-to-treat analysis will be performed.

NCT ID: NCT04689815 Recruiting - NPMc+ AML Clinical Trials

Oral Arsenic Trioxide for NPM1-mutated AML

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

A prospective open-label phase 2 study will be designed to assess the efficacy of oral arsenic trioxide plus azacitidine in preventing relapses in patients with NPM1-mutant AML. After screening and eligibility assessment, patients will receive treatment with oral arsenic trioxide plus azacitidine for 12 months. The recruitment period will last for 24 months and it will take approximately 36 months for study completion.

NCT ID: NCT04689802 Recruiting - Cancer Clinical Trials

To Identify Potential New Urine Marker Panel for Cancer Screening

Start date: January 20, 2021
Phase:
Study type: Observational

Polyamines are naturally produced metabolites in our cells. There were some reports suggested the urinary levels of polyamines were altered in patients with different cancers. This study is to explore the use of urinary polyamine for the diagnosis of common cancers.

NCT ID: NCT04689750 Recruiting - Clinical trials for Clonal Hematopoiesis

Donor CHIP and Allogeneic HSCT Outcome

Start date: January 1, 2021
Phase:
Study type: Observational

Current data on the impact of donor CHIP on long-term recipient outcome remain largely speculative. Data on the impact of donor CHIP including on allograft function, immunologic dysfunction, graft versus host disease (GVHD), disease relapse and survival across various donor populations are scarce. This is a retrospective-prospective cohort study designed to determine the association between donor gene mutations and outcome following allogeneic HSCT.

NCT ID: NCT04688866 Recruiting - Preterm Birth Clinical Trials

Investigation Into the Microorganisms in Pregnant Women

Start date: June 5, 2012
Phase:
Study type: Observational

Pregnant women with short cervical length (<25 mm) in second-trimester ultrasonographic assessment are at high risk for preterm birth, a major cause of perinatal mortality and morbidity worldwide. Some of these short-cervix women proceed to a more advanced stage manifested as a painless prematurely dilated cervix in the second trimester. It is not fully understood why some women have short cervical length or prematurely dilated cervix (cervical insufficiency), although evidence is mounting that there is an association between short cervical length and infection by microorganisms. The investigators hypothesize that the cervical microorganisms in pregnant women with a shortened or dilated cervix are different, compared with those in women with normal cervical length and a closed cervix.

NCT ID: NCT04687176 Recruiting - Clinical trials for Acute Promyelocytic Leukemia

Frontline Oral Arsenic Trioxide for APL

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

The investigators have formulated an oral preparation of arsenic trioxide (oral-ATO), and shown that it is efficacious for APL in R1, inducing CR2 in more than 90% of patients [8,9]. Furthermore, in an effort to prevent relapse, the investigators have moved oral-ATO forward to the maintenance of CR1. This strategy results in favorable overall-survival (OS) and leukemia-free-survival (LFS) [10], implying that prolonged treatment with oral-ATO may prevent relapses. Current protocols have incorporated i.v.-ATO in the treatment of newly-diagnosed APL [11-15]. For regimens comprising oral-ATO, ATRA and chemotherapy, 5-year OS in excess of 90% is achieved [11-15]. The investigators have also published long-term data showing the use of oral-ATO is highly effective and safe in the relapsed and frontline settings [16,17]. In this study, the investigators evaluate the use of oral-ATO and ATRA based induction regimens in newly diagnosed patients with APL with no of minimal chemotherapy in a prospective multicentre phase 2 study.

NCT ID: NCT04685928 Recruiting - Prostate Cancer Clinical Trials

Extended Systematic Versus Mri-Assisted pRostate Transperineal Biopsy

SMART
Start date: May 27, 2021
Phase: N/A
Study type: Interventional

This is a randomized controlled trial to evaluate the detection of clinically significant prostate cancer (csPCa) by MRI-targeted approach (MRI-arm) versus 24-core transperineal (TP) systematic biopsy (TP-arm). Clinically significant prostate cancer (csPCa) is defined as ISUP (International Society of Urogenital Pathology) Grade group ≥2 prostate cancer. Patients with elevated PSA 4-20 ng/mL with or without abnormal digital rectal examination (DRE) will be randomized in a 1:1 manner to MRI-arm or TP-arm. In the MRI-arm, multiparametric MRI prostate will be performed for each subject. MRI prostate is considered abnormal if PI-RADS (Prostate Imaging-Reporting and Data System, version 2.1) score is 3, 4 or 5. For subjects in MRI-arm with abnormal MRI, MRI-targeted biopsy will be performed, followed by 12-core systematic transperineal biopsy (sparing MRI-target). For subjects in MRI-arm with normal MRI, no biopsy is performed. For subjects in TP-arm, 24-core systematic transperineal biopsy will be performed without MRI guidance. The study flowchart is provided in Figure 1. The detection rates of csPCa will be compared between MRI-targeted biopsy plus 12-core systematic biopsy (in MRI-arm) versus TP-arm. The study hypothesis is MRI-guided prostate biopsy with 12-core systematic biopsy is superior to 24-core transperineal systematic biopsy in detection of csPCa.

NCT ID: NCT04681131 Recruiting - Clinical trials for Non-Small-Cell Lung Cancer

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Start date: March 17, 2021
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

NCT ID: NCT04672746 Recruiting - Adolescent Behavior Clinical Trials

Peer-delivered Brief Motivational Interviewing Via Instant Messaging Interaction in Reducing the Drug Abuse Among Youth

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

This is a two-arm, parallel-group, randomized controlled trial with an allocation ratio 1:1, by comparing the 12-month drug abuse reduction between the youth drug abusers who are individually randomized to participate in the intervention group receiving medical peer-delivered intervention of interactive brief motivational interviewing via instant messaging communication and those in the control group receiving general health information.

NCT ID: NCT04669223 Recruiting - Clinical trials for Pleural Effusion, Malignant

Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

Malignant pleural effusion (MPE) is a very common medical condition, especially among patients with disseminated cancers. Chest drain insertion aims to drain the pleural fluid collection and relieve dyspnea. Small bore chest tubes are recommended as the first line therapy for draining pleural effusions. However, there is no clinical data available to inform on the size of drains for better drainage. This is a randomized study comparing the two common bores of small bore chest drains in Hong Kong, and assess for its clinical efficacy and complication risks.